Reddy Vivek Y, Pollak Scott, Lindsay Bruce D, McElderry H Thomas, Natale Andrea, Kantipudi Charan, Mansour Moussa, Melby Daniel P, Lakkireddy Dhanunjaya, Levy Tzachi, Izraeli David, Sangli Chithra, Wilber David
Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Florida Hospital, Cardiovascular Research, Orlando, Florida, USA.
JACC Clin Electrophysiol. 2016 Nov;2(6):691-699. doi: 10.1016/j.jacep.2016.07.014. Epub 2016 Nov 21.
This study sought to assess the correlation between catheter and tissue contact force (CF) stability and 12-month clinical success for atrial fibrillation (AF) ablation.
The SMART-AF (Thermocool Smarttouch Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation) multicenter trial provided a robust dataset of AF ablation procedures, using the CF sensing ablation catheter.
CF and CF stability were correlated with 12-month success for drug-refractory symptomatic AF ablation. CF stability was assessed by stability of ablation parameters (CF, time, location stability) over 3-dimensional electroanatomic maps of pulmonary veins (PVs) using a new proprietary software module and the percentage of time within investigator-selected CF ranges. Available data for potential "PV gaps" were retrospectively identified when stability criteria were not met and were correlated with 12-month success.
Average CF categories of 0 to 10, 10 to 20, and >20 g were associated with 12-month success rates of 90%, 70%, and 70%, respectively; thus, higher average CF did not correlate with treatment success. An exploratory univariate analysis showed significantly higher success rates with a CF of 6.5 to 10.3 g than with <6.5 g (odds ratio: 2.95; 95% confidence interval: 1.13 to 7.72; p = 0.028) but a CF >10 g did not improve success. When stable CF was applied ≥73% of the time within the preselected CF range, success improved. A receiver operating characteristic curve analysis revealed that PV gaps exceeding 10.6-mm distance significantly correlated with 12-month failure.
In the SMART-AF trial, CF stability with sufficient CF was most predictive of optimal 12-month success. (Thermocool Smarttouch Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation [SMART-AF]; NCT01385202).
本研究旨在评估导管与组织接触力(CF)稳定性与心房颤动(AF)消融12个月临床成功率之间的相关性。
SMART-AF(用于治疗症状性阵发性心房颤动的Thermocool Smarttouch导管)多中心试验提供了一个强大的AF消融手术数据集,使用了CF传感消融导管。
CF和CF稳定性与药物难治性症状性AF消融的12个月成功率相关。使用新的专有软件模块,通过肺静脉(PVs)三维电解剖图上消融参数(CF、时间、位置稳定性)的稳定性以及研究者选择的CF范围内的时间百分比来评估CF稳定性。当未满足稳定性标准时,回顾性确定潜在“PV间隙”的可用数据,并将其与12个月成功率相关联。
平均CF类别为0至10、10至20和>20 g时,12个月成功率分别为90%、70%和70%;因此,较高的平均CF与治疗成功率无关。一项探索性单因素分析显示,CF为6.5至10.3 g时的成功率显著高于<6.5 g时(优势比:2.95;95%置信区间:1.13至7.72;p = 0.028),但CF>10 g并不能提高成功率。当在预选CF范围内≥73%的时间应用稳定CF时,成功率提高。受试者工作特征曲线分析显示,距离超过10.6 mm的PV间隙与12个月失败显著相关。
在SMART-AF试验中,具有足够CF的CF稳定性最能预测12个月的最佳成功率。(用于治疗症状性阵发性心房颤动的Thermocool Smarttouch导管[SMART-AF];NCT01385202)